Abivax completes pre-NDA meeting with FDA for ulcerative colitis drug
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall St set to open lower after AI-led selloff; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Nokia shares fall despite earnings beat on cash flow concerns
Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod
July 30, 2026 4:05 PM EDTAbivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod
Company remains on track to submit its first New Drug Application for obefazimod for the treatment of moderately to severely active ulcerative colitis by the end of 2026
PARIS, France July 30, 2026 10:05 p.m. CEST Abivax SA (Euronext Paris: FR0012333284 ABVX / Nasdaq: ABVX) (Abivax or the Company), a clinical-stage biotechnology... More



